Myriad Genetics Names Raj Jampa as New Chief Technology Officer

Myriad Genetics (NASDAQ: MYGN) appointed Raj Jampa as chief technology officer effective June 1, 2026.

Rhea-AI Summary

Myriad Genetics (NASDAQ: MYGN) appointed Raj Jampa as chief technology officer effective June 1, 2026. He will lead technology strategy and execution, including expanding AI use to improve efficiency, digital foundations, and customer experience, supporting Myriad’s molecular diagnostics and precision medicine growth strategy.

Argus Jun 2 session

+0.70% close to close Open Argus

Details

News Market Reaction – MYGN

On Jun 2, the day this news came out, MYGN closed 0.70% above the previous close.

Data tracked by StockTitan Argus for the Jun 2 session.

Market Context

This announcement installs a new CTO focused on modernizing technology infrastructure and expanding ...

Analysis

This announcement installs a new CTO focused on modernizing technology infrastructure and expanding AI capabilities across Myriad’s diagnostics platform. It follows recent AI product launches and ASCO data updates, reinforcing the company’s technology-first strategy. With shares trading below the 200-day MA of $5.96 and well under the 52-week high of $8.59, investors may watch how this leadership change supports execution, capital allocation under the $200,000,000 shelf, and future financial performance.

Key Figures

CTO effective date: June 1, 2026

CTO effective date

June 1, 2026

Start date for new chief technology officer role

Historical Context

5 past events · Latest: May 27

5 events

1. May 27

   ASCO MRD data

   24h Move

   +2.1%

   New Precise MRD assay data and ASCO presence supported modest share gains.

2. May 26

   AI product launch

   24h Move

   +2.1%

   Launch of Prolaris + AI prostate cancer test drove a positive price reaction.

3. May 15

   Patient story campaign

   24h Move

   -1.1%

   Hereditary cancer awareness partnership coincided with a small share move.

4. May 07

   Investor conferences

   24h Move

   +4.9%

   Upcoming healthcare conferences and investor meetings were met with share gains.

5. May 05

   Q1 2026 earnings

   24h Move

   -18.3%

   Modest revenue growth but larger net loss triggered a sharp selloff.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

molecular diagnostic testing, precision medicine, chief technology officer, AI

4 terms

molecular diagnostic testing medical

"Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine..."

Molecular diagnostic testing uses tools that read the genetic material or specific molecules from a tissue, blood, or swab sample to detect disease, identify pathogens, or predict how a patient will respond to treatment. Think of it like a highly detailed fingerprint check for the biology of an illness. Investors care because these tests drive sales, regulatory scrutiny, and reimbursement decisions, so accuracy, adoption, and approval directly affect a company’s revenue and growth prospects.

precision medicine medical

"Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine..."

Precision medicine uses a person’s unique genetic makeup, lifestyle and environment to choose treatments and preventive steps that are more likely to work for them than one-size-fits-all approaches. For investors, it matters because it can make therapies more effective and efficient—think tailoring a suit rather than buying off the rack—affecting drug development costs, market size, pricing power and the speed at which therapies win regulatory approval.

chief technology officer technical

"...announces today the appointment of Raj Jampa as chief technology officer (CTO)..."

The chief technology officer is the senior executive who sets a company's technology vision and oversees development, engineering, and technical operations—think of them as the lead architect and head mechanic who decides what tools the business builds and how they run. Their choices affect product direction, cost structure, cybersecurity and scalability, so investors watch the CTO to gauge a company’s ability to innovate, compete and manage technical risk.

AI technical

"...including further leveraging AI to drive increased efficiency and effectivity."

Artificial intelligence (AI) is technology that enables machines to mimic human thinking and learning, allowing them to analyze information, recognize patterns, and make decisions. For investors, AI matters because it can improve how businesses operate, create new products, or identify opportunities faster and more accurately than humans alone, potentially impacting company success and market trends.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SALT LAKE CITY, June 02, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announces today the appointment of Raj Jampa as chief technology officer (CTO), effective June 1, 2026.

“Raj is a proven technology leader with the vision and execution experience to help scale our business and accelerate technology innovation across the enterprise,” said Sam Raha, Chief Executive Officer, Myriad Genetics. “His leadership will be instrumental in strengthening our digital technology foundation, enhancing customer experience and supporting the next phase of Myriad’s growth and value creation.”

As CTO, Jampa will be responsible for strategy and execution of Myriad’s technology organization, including further leveraging AI to drive increased efficiency and effectivity.

“I’m honored to join Myriad at such an important time in its growth,” said Jampa. “I look forward to partnering across the enterprise to modernize our technology foundation, scale data and AI capabilities, and deliver solutions that create meaningful impact for patients, providers and the business.”

Before joining Myriad Genetics, Jampa held senior technology leadership roles at Agilent Technologies, Exact Sciences and Genomic Health, where he led large-scale transformation initiatives across enterprise platforms, digital capabilities and operating models. His experience modernizing technology infrastructure and scaling AI-enabled capabilities positions him well to help advance Myriad’s growth strategy and mission.

About Myriad Genetics 
Myriad Genetics is a leading molecular diagnostic and precision medicine company committed to advancing health and well-being for all. Myriad Genetics develops and commercializes molecular tests that help patients and providers uncover genetic insights. Our tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care, support earlier detection, enable more precise treatment and contribute to lowering healthcare costs. For more information, visit myriad.com.

Myriad Genetics Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements that Jampa’s leadership will be instrumental in strengthening Myriad’s digital technology foundation, enhancing customer experience and supporting the next phase of Myriad’s growth and value creation . These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 24, 2026, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law. 

Investor Contact 
Matt Scalo 
(801) 584-3532 
IR@myriad.com 

Media Contact 
Kate Schraml
(224) 875-4493
PR@myriad.com  

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who is the new CTO of Myriad Genetics (NASDAQ: MYGN) in 2026?

The new CTO of Myriad Genetics is Raj Jampa, effective June 1, 2026. According to Myriad Genetics, he will oversee technology strategy and execution, with a focus on AI, digital infrastructure, and customer experience across the enterprise.

What are Raj Jampa’s responsibilities as CTO at Myriad Genetics (MYGN)?

As CTO, Raj Jampa is responsible for technology strategy and execution at Myriad Genetics. According to Myriad Genetics, his role includes modernizing the technology foundation, scaling data and AI capabilities, and supporting efficiency, customer experience, and overall business growth.

When did Raj Jampa officially start as CTO of Myriad Genetics (MYGN)?

Raj Jampa’s appointment as CTO at Myriad Genetics became effective on June 1, 2026. According to Myriad Genetics, he joins at a key growth stage to help scale technology, data, and AI capabilities across the company’s molecular diagnostics and precision medicine operations.

What experience does Raj Jampa bring to Myriad Genetics as CTO?

Raj Jampa brings senior technology leadership experience from Agilent Technologies, Exact Sciences, and Genomic Health. According to Myriad Genetics, he has led large-scale transformations across enterprise platforms, digital capabilities, operating models, and AI-enabled technologies, directly relevant to Myriad’s growth strategy.

How will AI be used under the new Myriad Genetics CTO, Raj Jampa?

Myriad Genetics plans to further leverage AI under Raj Jampa’s leadership. According to Myriad Genetics, his mandate includes using AI to increase efficiency and effectiveness, scale data-driven capabilities, and deliver technology solutions that benefit patients, healthcare providers, and the business.

Why did Myriad Genetics appoint Raj Jampa as CTO in June 2026?

Myriad Genetics appointed Raj Jampa to support its next phase of growth and value creation. According to Myriad Genetics, his track record in digital transformation, technology modernization, and AI-enabled capabilities is expected to strengthen the company’s technology foundation and customer experience.